Home › Cancro della vescica › Tennessee
Studi clinici su Cancro della vescica nello stato di Tennessee
34 studi su Cancro della vescica cercano partecipanti presso sedi nello stato di Tennessee.
Città nello stato di Tennessee
Testo ufficiale dello studio (inglese)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06465069A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- SCRI Oncology Partners, Nashville
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06760819A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
- The Conrad Pearson Clinic ( Site 0143), Germantown
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06833073A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06172478A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07090499Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
- The West Clinic - Wolf River, Germantown
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07061964Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
- SCRI Oncology Partners, Nashville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT07566156Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Vanderbilt University/Ingram Cancer Center, Nashville
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT03866382Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- Tennessee Oncology, PLLC - Chattanooga Downtown, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga Med Park II, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga Memorial, Chattanooga
- e altri 20
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07421700A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
- Urology Associates, P.C., Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07206225A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07277413DESTINY-PANTUMOUR04
- Research Site, Nashville
In reclutamentoStudio osservazionale
Età da 18 a 130 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07124000A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
- The West Clinic, P.C. ( Site 0791), Germantown
- Thompson Cancer Survival Center ( Site 0803), Knoxville
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0831), Nashville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07419295A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07218380Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Sarah Cannon Research Institute, Nashville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 set 2026 · NCT05267626A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
- SCRI, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 set 2026 · NCT07217171First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT06644755Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
- The Conrad Pearson Clinic (Urology America), Germantown
- Urology Associates, PC, Nashville
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT06567743Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
- Conrad Person Clinic, Memphis
- Urology Associates PC, Nashville
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 ago 2026 · NCT05951179FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Sarah Cannon and HCA Research Institute, Nashville
- Tennessee Oncology, Nashville
- Vanderbilt University Medical Center, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 ago 2026 · NCT05614739Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
- Research Site, Nashville
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 ago 2026 · NCT07129993Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT07097142A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 ago 2026 · NCT05592626LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- Urology Associates, P.C., Nashville
- Vanderbilt Univerity Medical Center, Nashville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 ago 2026 · NCT04752722Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
- Vanderbilt University Medical Center, Nashville
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 31 lug 2026 · NCT07225127Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
- SCRI Oncology Partners, Nashville
- Local Institution - 0084, Nashville
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 lug 2026 · NCT07106762A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- SCRI - TriStar Medical Group Children's Specialists, Nashville
- SCRI Oncology Partners, Nashville
In reclutamentoFase 2
Età 8 e oltre · Tutti i sessi · Aggiornato il 27 lug 2026 · NCT05503797An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
- Research Site, Nashville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 lug 2026 · NCT07720284A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- University of Tennessee Medical Center, Knoxville
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 lug 2026 · NCT04879329A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- US Oncology Research LLC, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 lug 2026 · NCT04389632Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
- Vanderbilt University Medical Center, Nashville
In reclutamento
Età da 18 a 88 · Tutti i sessi · Aggiornato il 2 lug 2026 · NCT06394869A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 feb 2026 · NCT06778863cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist (BHMCC), Memphis
- Vanderbilt-Ingram Cancer Center, Nashville
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età 40 e oltre · Tutti i sessi · Aggiornato il 20 gen 2026 · NCT05366881SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
In reclutamentoStudio osservazionale
Tutte le età · Tutti i sessi · Aggiornato il 28 ott 2025 · NCT03452774Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.